🧬 Noam Solomon - Immunai - Part 4 | How Searching for Investors is Like Finding a Life Partner | Luck In Fundraising | The Optimal Features of the Immune System | The Advice to Take More Risks
August 22, 2024
Part 4 of 4.
My guest for this week’s episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.
As a podcast listener, you can redeem exclusive discounts with a growing list of biotech vendors and get $500 off your first equipment lease by using promo code “TBSP” on https://www.excedr.com/rewards.
Part 4 of 4.
Part 4 of 4.
My guest for this week’s episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.
Prior to co-founding Immunai, Noam had a career in both industry and academia. Noam has a double PhD in math and computer science and served as a postdoctoral researcher at MIT and Harvard. Noam also worked as an algorithms developer, consultant, and head of data science in several high-tech companies in Israel. Noam's extensive background in math, computer science, AI, and machine learning gives him a unique depth of experience that founders can learn from.
Join us this week and hear about:
- Noam's unique dynamics of working with academic institutions and the alignment of incentives that come with collaborating with top researchers
- The importance of strategic partnerships and the meticulous analysis involved in selecting the right collaborators
- Noam’s fundraising journey
- The technological advancements at Immunai
- The application of AI in optimizing drug development processes
Please enjoy my conversation with Noam Solomon.
Timestamps:
Timestamps:
00:00 Intro
01:35 Episode starts, screening for the right business partners and determining what projects to take on and which ones to pass
07:40 Noam’s philosophy and tips on fundraising
15:47 What to expect of Immunai in the next year or two
19:30 Shout outs for help along his journey
21:47 Advice to your 21-year old self
24:15 Outro
Find Our Guest, Noam Solomon, at this link:
Find Our Host, Jon Chee, at these links:
Social & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Enriched Notes:
Topics Mentioned:
Biotech Startup Support https://www.excedr.com/resources-category/biotech-startup-support
Biotech Funding for Startups: What Are Your Options? https://www.excedr.com/resources/biotech-startup-funding-options
How to Get Funding for Lab Research in 2024 https://www.excedr.com/blog/how-to-get-funding-for-lab-research
How to Raise Money from Angel Investors https://www.excedr.com/resources/angel-funding-and-angel-investors
What Is Series A, B, & C Funding? Series Funding Explained https://www.excedr.com/resources/series-funding-explained
How to Fund an R&D Startup: First Steps a Founder Can Take https://www.excedr.com/resources/rd-startup-funding-first-steps
Biotech Partnerships: How Partnering with Big Pharma Can Support R&D https://www.excedr.com/blog/how-biotech-partnerships-support-research
What Should Investors & Founders Expect From Each Other? https://www.excedr.com/resources/investor-founder-expectations
People Mentioned
Luis F. Voloch https://www.linkedin.com/in/luisvoloch/
Ansu Satpathy https://www.linkedin.com/in/ansu-satpathy-67a5a9193/
The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.